Topiramate Use in Elderly Patients: Safety, Contraindications, and Monitoring

Evidence Base and Dosing Considerations

Topiramate can be used cautiously in elderly patients (e.g., 69 years old), but high‑quality data specifically guiding its use in the geriatric population are lacking; dose adjustments should be based on renal function. 1, 2
Phase 3 trials of phentermine‑topiramate extended‑release enrolled participants up to 70 years of age, yet no high‑quality evidence exists to direct therapy in the geriatric subgroup. 1, 2, 3

The combination should be avoided in patients with a history of cardiovascular disease or uncontrolled hypertension. 1, 2, 3
Blood pressure and heart rate should be monitored periodically, especially during the first 12 weeks of therapy. 1, 4, 5
In clinical trials, systolic/diastolic blood pressure generally declined, with only modest increases in heart rate observed at higher doses. 1, 2, 3

Cognitive impairment, reduced concentration/attention, and memory problems are the most frequently reported neurocognitive adverse events. 6, 7, 3
Psychiatric side effects—including depression, nervousness, and psychomotor slowing—have also been documented. 6, 7
Gastrointestinal complaints such as constipation, dry mouth, and altered taste (dysgeusia) occur in this population. 3

Topiramate’s carbonic anhydrase inhibition can induce metabolic acidosis; periodic serum bicarbonate monitoring is advised for long‑term users. 1, 2, 3
High doses and prolonged exposure may increase the risk of nephrolithiasis due to elevated urine pH, hypercalciuria, and hypocitraturia. 1, 2, 3

Topiramate is contraindicated in patients with glaucoma, particularly acute angle‑closure glaucoma. 6, 8
When combined with phentermine, it should be avoided in patients with untreated hyperthyroidism. 1, 2, 3
Use within 14 days of monoamine oxidase inhibitor therapy is prohibited when combined with phentermine. 1, 2, 3

Cardiovascular monitoring: Measure blood pressure and heart rate regularly, with heightened vigilance during the initial 12 weeks if phentermine is co‑administered. 1, 4, 5
Renal/metabolic monitoring: Assess renal function before initiation and periodically thereafter; monitor serum bicarbonate levels during long‑term therapy. 1, 2, 3
Neuropsychiatric monitoring: Evaluate patients for cognitive decline and psychiatric symptoms throughout treatment. 6, 7, 3